01/13/2016

CURES 2.0 enrollment now open to dentists


All dentists who are authorized to prescribe, order, administer, furnish or dispense controlled substances must register in the Controlled Substance Utilization Review and Evaluation System (CURES) by July 1 and have updated browsers to access the system. Dispensed controlled substance prescriptions are recorded in CURES, which allows prescribers to look up a patient's controlled substance current usage and past history.

To access CURES 2.0, dentists are required to use Microsoft Internet Explorer Version 11.0 or greater, Mozilla FireFox, Google Chrome or Safari. Access to the current CURES 1.0 is available for now, but the Department of Justice told CDA that dentists should have up-to-date browsers within the first half of the year to retain access to the CURES database.

Previously, CURES 2.0 was planned to be in use by Jan.1 of this year, however, the system rollout was not meeting important deadlines. The governor signed AB 679 (Allen), which CDA supported, moving the deadline for required registration to the new, July 1 date.

Prescribers in the United States write nearly 100 percent of opioid prescriptions worldwide, and in California alone more than 1 billion dosage units of hydrocodone combination products were dispensed in the 2013-14 fiscal year. Opioid use and deaths attributed to abuse are sharply on the rise, sending government agencies and public health advocates looking for tools to turn the tide. The CURES system upgrade and the requirement for prescribers to register by July 1, as well as last year's Schedule II reclassification of opioid combination drugs, are all part of these efforts.

The CURES requirement was established in 2013 (SB 809 DeSaulneir), and directs the DOJ, in conjunction with the Department of Consumer Affairs (DCA) and licensing boards like the Dental Board of California, to develop a streamlined application and approval process to provide access to the CURES database, also known as the California Prescription Drug Monitoring Program (PDMP), for licensed health care practitioners and pharmacists.

CDA will share information about CURES in the CDA Update, e-newsletter and on cda.org as it becomes available. If dentists have any questions they can email cures@doj.ca.gov. To register, visit oag.ca.gov/cures. For more information on the current science and practice of pain management in dentistry, see the November 2015 CDA Journal at cda.org/journal.



Related Items

In 2013, more than 137 million prescriptions of hydrocodone were dispensed in the U.S. Unfortunately, these drugs are also the most addictive and potentially deadly of prescription drugs. In the midst of intensified focus on opioid analgesics and rising abuse rates, public health agencies and government regulators are responding, and thoughtful, evidence-based prescribing is a necessity. With such an important and prominent issue, The Dentists Insurance Company (TDIC) offers advice to dentists.

The CURES enrollment deadline for providers has officially been pushed back from Jan. 1 to July 1 of 2016. The change comes after the governor signed AB 679 (Allen). The bill was amended late in the legislative session due to concern that the most recent Controlled Substance Utilization Review and Evaluation System (CURES) update has fallen behind schedule. The CURES 2.0 was planned to be in use by July 1 of this year, yet the system is still not fully operational. The delay will give the Department of Justice (DOJ) time to finalize CURES 2.0 and for providers to enroll.

All dentists who are authorized to prescribe, order, administer, furnish or dispense controlled substances must register for the Controlled Substance Utilization Review and Evaluation System (CURES) by Jan. 1, 2016. CDA Update staff asked the Department of Justice about the new CURES 2.0 system and what dentists should do to register and ensure their systems are compatible.

All dentists who are authorized to prescribe, order, administer, furnish or dispense controlled substances must register for the Controlled Substance Utilization Review and Evaluation System (CURES) by Jan. 1, 2016. In addition, the Department of Justice and the Department of Consumer Affairs recently announced that a new CURES 2.0 went live on July 1. This upgraded prescription drug monitoring program features a variety of performance improvements and added functionality.

CDA and a coalition of more than 600 organizations helped defeat Proposition 46 in last year’s election, but a piece of the ballot measure has reappeared in the form of a new bill. CDA-opposed SB 482, authored by Sen. Ricardo Lara (D-Bell Gardens), revisits a provision included in Proposition 46 last year dealing with the state’s Controlled Substance Utilization Review and Evaluation System  (CURES) online prescription drug database.

In California, more than 1 billion dosage units of hydrocodone combination products were dispensed in the 2013-14 fiscal year, according to the state’s Controlled Substance Utilization Review and Evaluation System (CURES). What's more, approximately 100 percent of the hydrocodone use worldwide occurs in the U.S., according to Tony J. Park, PharmD, JD, who co-hosted a lecture on the topic at CDA Presents The Art and Science of Dentistry in Anaheim on May 2.

Topics
Top